PoliCheck Network
← Back to bills
H.R. 9474119th CongressReferred to the House Committee on Agriculture.

Local Foods for Healthy Schools Act of 2026

Introduced: Jun 25, 2026
Latest action: Jun 25, 2026

Latest Action

Referred to the House Committee on Agriculture.

1
Primary Sponsors
4
Cosponsors
2
Recorded Actions
0
Linked Votes

Plain-English AI Summary

What this bill means

Generated from the official bill text to make the legislation easier to understand.

Not Generated

A plain-English AI summary has not been generated for this bill yet.

Official Summary

Official legislative summary associated with this bill.

No official summary is currently available.

Primary Sponsors

Members listed as primary sponsors of this legislation.

Cosponsors

Members who joined this legislation as cosponsors.

Recorded Actions

Official legislative actions recorded for this measure.

H11100Jun 25, 2026

Referred to the House Committee on Agriculture.

Official source ↗
Intro-HJun 25, 2026

Introduced in House

Official source ↗

Linked Votes

Roll-call votes associated with this legislation.

No roll-call votes are currently linked to this bill.

Lobbying Activity

Federal lobbying disclosures that explicitly identify H.R. 9474. These records show reported lobbying involving the legislation; they do not establish that every member of Congress, sponsor, or voter was personally contacted.

NATIONAL EDUCATION ASSOCIATION

Registrant: NATIONAL EDUCATION ASSOCIATION

2nd Quarter (Apr 1 - June 30)
Jul 22, 2026

Reported lobbying issue

Education: Department of Education Interagency Agreements Elementary & Secondary Education Act Higher Education Secure Rural Schools E-Rate Teacher Pay Child Nutrition Graduated Corporate Tax Act S 4407/HR 7985, CHATBOT Act S 4297/HR 8800, FY27 National Defense Authorization Act S J Res 196, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Education relating to "Reimagining and Improving Student Education-Federal Student Loan Program Final Regulations" HR 2003, Affordable Loans for Students Act HR 7567, Farm, Food & National Security Act S 4864, PUPIL Act S 4914/HR 9467, Green Ribbon Act H J Res 155, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Education relating to "William D. Ford Federal Direct Loan (Direct Loan) Program" HR 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 HR 9272, Parent PLUS Loan Fairness & Responsibility Act S 4733/HR 9245, Beginning Educators Mentorship & Retention Act S 4689, Reading Excellence & Achievement Act HR 7890, Science of Reading Act HR 9474, Local Foods for Healthy Schools Act S 3321, FAIR Leave Act HR 6617, Keeping All Students Safe Act HR 7259, Military Dependents School Meal Eligibility Act S 4415/HR 9628, TEACH Improvement Act S 4597/HR 8937, Early Childhood Workforce Advancement Act S J Res 182, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Education relating to "William D. Ford Federal Direct Loan (Direct Loan) Program" HR 8728, Feed Our Kids Act S 2828/HR 9224, Child Care Modernization Act S 4567/HR 8896, Loan Forgiveness for Educators Act S 4843/HR 8978, Enhancing Mental Health & Suicide Prevention Through Campus Planning Act S 4618/HR 8979, Elementary & Secondary School Counseling Act S 4504/HR 8752, Full-Service Community School Expansion Act HR 8815, Teacher Debt Relief Act S 4518/HR 8798, Universal School Meals Program Act HR 6413, Workforce Flexibility Act HR 8606, CHARTER Act HR 2616, Stopping Indoctrination & Protecting Kids Act S 4449/HR 8636, Strengthening Educator Workforce Data Act HR 1524, ALYSSA Act S Con Res 33, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2026 and setting forth the appropriate budgetary levels for fiscal years 2027 through 2035 HR 8210, A Stronger Workforce for America Act HR 7082, FLEX Act HR 2333, Protecting Students with Disabilities Act HR 8356, Clean Slate Through Consolidation Act S 4468/HR 4120, Supporting the Mental Health of Educators and Staff Act Government Issues: Department of Education Interagency Agreements Secure Rural Schools Elementary and Secondary Education Act Charter Repeal Perkins Loans Labor Issues/Antitrust/Workplace: S 844/HR 5408, Faster Labor Contracts Act S 3321/HR 3404, FAIR Leave Act HR 4763, Protected Time Off Act S 2837, Protect America's Workforce Act HR 8555, Living Wage For All Act HR 6413, Workforce Flexibility Act HR 5390, FAMILY Act Defense: S 4297/HR 8800, FY2027 National Defense Authorization Act Immigration: S Con Res 33, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2026 and setting forth the appropriate budgetary levels for fiscal years 2027 through 2035 Budget/Appropriations: HR 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S Con Res 33, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2026 and setting forth the appropriate budgetary levels for fiscal years 2027 through 2035 Taxation/Internal Revenue Code: Graduated Corporate Tax Act Various Tax Concepts S 4297/HR 9289, Keep Public Funds in Public Schools Act Civil Rights/Civil Liberties: NEA Charter Repeal EEOC S 1383, SAVE America Act S 3365/HR 6440, Right to Read Act S 4369, Absentee & Mail Voter Protection Act HR 2386, Make Education Great Again Act Health Issues: REFRESH Act S 4407/HR 7985, CHATBOT Act HR 6440, Right to Read Act

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $670,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

UNITED FOR PATENT REFORM

Registrant: TWINLOGIC STRATEGIES, LLP

1st Quarter (Jan 1 - Mar 31)
Feb 26, 2025

Reported lobbying issue

Copyright/Patent/Trademark: Issues related to patent quality, Inter Partes Review, and the Patent Trial and Appeal Board (PTAB). Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370 (in the 118th Congress); Patent Eligibility Restoration Act, S. 2140 and HR 9474 (in the 118th Congress); RESTORE Patent Rights Act of 2024, S. 4840 and HR 9221 (in the 118th Congress).

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

2nd Quarter (Apr 1 - June 30)
Jul 20, 2026

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act S. 1095. The Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 2276/H.R. 3269 Eliminating Thickets to Increase Competition Act (Ethics Act) S. 326 / H.R. 861 American Music Fairness Act of 2025 Proposed changes to address counterfeit use of trademarks, such as the SHOP SAFE Act introduced in the last Congress S. 43 / H.R. 6485 - Skinny Labels, Big Savings Act Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues H.R. 4780 - USTRx Act

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $90,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

1st Quarter (Jan 1 - Mar 31)
Apr 20, 2026

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act S. 1095. The Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 2276/H.R. 3269 Eliminating Thickets to Increase Competition Act (Ethics Act) S. 326 / H.R. 861 American Music Fairness Act of 2025 Proposed changes to address counterfeit use of trademarks, such as the SHOP SAFE Act introduced in the last Congress Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $90,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

4th Quarter (Oct 1 - Dec 31)
Jan 20, 2026

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act S. 1095. The Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 2276/H.R. 3269 Eliminating Thickets to Increase Competition Act (Ethics Act) S. 326 / H.R. 861 American Music Fairness Act of 2025 Proposed changes to address counterfeit use of trademarks, such as the SHOP SAFE Act introduced in the last Congress Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $90,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

3rd Quarter (July 1 - Sep 30)
Oct 20, 2025

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act S. 1095. The Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 2276/H.R. 3269 Eliminating Thickets to Increase Competition Act (Ethics Act) Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $90,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

1st Quarter (Jan 1 - Mar 31)
Oct 20, 2025

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024 S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $60,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

2nd Quarter (Apr 1 - June 30)
Oct 20, 2025

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $80,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COLLEGE OF AMERICAN PATHOLOGISTS

Registrant: COLLEGE OF AMERICAN PATHOLOGISTS

3rd Quarter (July 1 - Sep 30)
Oct 17, 2025

Reported lobbying issue

Health Issues: H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 HR 3164 - Ensuring Community Access to Pharmacy Services Act (ECAPS) S 2800 - Pharmacy and Medically Underserved Areas Enhancement Act S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to tariffs Issues related to public health Medicare/Medicaid: FY 2026 Appropriations Student VISA issues Price Tags / Transparency Legislation CDC funding NIH Funding CLIAC reinstatement Issues relating to surprise medical bills Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Advocating for relief from cuts to evaluation and management codes within Medicare Issues relating to the debt limit Issues relating to site-neutral payments Issue relating to artificial intelligence Issues relating to combatting fentanyl crisis Issues relating to Medicare coverage pathways Researching Long Covid Fees paid on electronically submitting to insurers Issues relating to the Clinical Laboratory Fee Schedule Issues relating to forensic pathologist loan repayment Funding for the CDC AMD program Funding for lab test harmonization Issues surrounding Health Data Privacy Issues surrounding the Change Healthcare Cyber Attack Medicare payment reform S.4338 - Pay PCPs Act of 2024 Challenges facing independent medicine PTAC Reform Issues relating to blood donations Issues relating to the local coverage determination process Issues relating to GME Issues relating to laboratory accreditation procedures of IVF centers Issues relating to site neutral payment reform Issues relating to Medicaid funding S. 2761 and H.R. 5269, the RESULTS Act Issues related to cancer Issues related to the Medicare Access and CHIP Reauthorization Act of 2015

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $124,816

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

2nd Quarter (Apr 1 - June 30)
Jul 21, 2025

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $50,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COLLEGE OF AMERICAN PATHOLOGISTS

Registrant: COLLEGE OF AMERICAN PATHOLOGISTS

2nd Quarter (Apr 1 - June 30)
Jul 18, 2025

Reported lobbying issue

Health Issues: H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Seniors timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act Medicare/Medicaid: FY 2026 Appropriations Student VISA issues Price Tags / Transparency Legislation CDC funding NIH Funding CLIAC reinstatement Issues relating to surprise medical bills Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Advocating for relief from cuts to evaluation and management codes within Medicare Issues relating to the debt limit Issues relating to site-neutral payments Issue relating to artificial intelligence Issues relating to combatting fentanyl crisis Issues relating to Medicare coverage pathways Researching Long Covid Fees paid on electronically submitting to insurers Issues relating to the Clinical Laboratory Fee Schedule Issues relating to forensic pathologist loan repayment Funding for the CDC AMD program Funding for lab test harmonization Issues surrounding Health Data Privacy Issues surrounding the Change Healthcare Cyber Attack Medicare payment reform S.4338 - Pay PCPs Act of 2024 Challenges facing independent medicine PTAC Reform Issues relating to blood donations Issues relating to the local coverage determination process Issues relating to GME Issues relating to laboratory accreditation procedures of IVF centers Issues relating to site neutral payment reform Issues relating to Medicaid funding

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $149,447

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COUNCIL FOR INNOVATION PROMOTION (C4IP)

Registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)

1st Quarter (Jan 1 - Mar 31)
Apr 21, 2025

Reported lobbying issue

Copyright/Patent/Trademark: General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024 S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 Trade (domestic/foreign): General advocacy in support of pro-IP/innovation policies ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $50,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

COLLEGE OF AMERICAN PATHOLOGISTS

Registrant: COLLEGE OF AMERICAN PATHOLOGISTS

1st Quarter (Jan 1 - Mar 31)
Apr 16, 2025

Reported lobbying issue

Health Issues: HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act Medicare/Medicaid: Issues relating to surprise medical bills Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Advocating for relief from cuts to evaluation and management codes within Medicare Issues relating to the debt limit Issues relating to site-neutral payments Issue relating to artificial intelligence Issues relating to combatting fentanyl crisis Issues relating to Medicare coverage pathways Researching Long Covid Fees paid on electronically submitting to insurers Issues relating to the Clinical Laboratory Fee Schedule Issues relating to forensic pathologist loan repayment Funding for the CDC AMD program Funding for lab test harmonization Issues surrounding Health Data Privacy Issues surrounding the Change Healthcare Cyber Attack Medicare payment reform S.4338 - Pay PCPs Act of 2024 Challenges facing independent medicine PTAC Reform Issues relating to blood donations Issues relating to the local coverage determination process Issues relating to GME Issues relating to laboratory accreditation procedures of IVF centers Issues relating to site neutral payment reform Issues relating to Medicaid funding

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $217,588

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

HIGH TECH INVENTORS ALLIANCE

Registrant: DAVID W JONES

2nd Quarter (Apr 1 - June 30)
Jul 17, 2026

Reported lobbying issue

Copyright/Patent/Trademark: I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826).

Government entities reported: Commerce, Dept of (DOC) Federal Trade Commission (FTC) HOUSE OF REPRESENTATIVES Justice, Dept of (DOJ) Patent & Trademark Office (PTO) SENATE White House Office

Reported filing-period amount: $110,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

HIGH TECH INVENTORS ALLIANCE

Registrant: DAVID W JONES

1st Quarter (Jan 1 - Mar 31)
Apr 21, 2026

Reported lobbying issue

Copyright/Patent/Trademark: I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act from last Congress, H.R.4370, S.2220), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act from last Congress (S.2140, H.R.9474). I have also supported disclosure of third-party litigation funding in patent cases (e.g., H.R.1109 - Litigation Transparency Act of 2025).

Government entities reported: Commerce, Dept of (DOC) Federal Trade Commission (FTC) HOUSE OF REPRESENTATIVES Justice, Dept of (DOJ) Patent & Trademark Office (PTO) SENATE White House Office

Reported filing-period amount: $110,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

HIGH TECH INVENTORS ALLIANCE

Registrant: DAVID W JONES

4th Quarter (Oct 1 - Dec 31)
Jan 19, 2026

Reported lobbying issue

Copyright/Patent/Trademark: I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act from last Congress, H.R.4370, S.2220), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act from last Congress (S.2140, H.R.9474). I have also supported disclosure of third-party litigation funding in patent cases (e.g., H.R.1109 - Litigation Transparency Act of 2025).

Government entities reported: Commerce, Dept of (DOC) Federal Trade Commission (FTC) HOUSE OF REPRESENTATIVES Justice, Dept of (DOJ) Patent & Trademark Office (PTO) SENATE White House Office

Reported filing-period amount: $110,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

HIGH TECH INVENTORS ALLIANCE

Registrant: DAVID W JONES

3rd Quarter (July 1 - Sep 30)
Oct 14, 2025

Reported lobbying issue

Copyright/Patent/Trademark: I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act from last Congress, H.R.4370, S.2220), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act from last Congress (S.2140, H.R.9474). I have also supported disclosure of third-party litigation funding in patent cases (e.g., H.R.1109 - Litigation Transparency Act of 2025).

Government entities reported: Commerce, Dept of (DOC) Federal Trade Commission (FTC) HOUSE OF REPRESENTATIVES Justice, Dept of (DOJ) Patent & Trademark Office (PTO) SENATE White House Office

Reported filing-period amount: $110,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

HIGH TECH INVENTORS ALLIANCE

Registrant: DAVID W JONES

2nd Quarter (Apr 1 - June 30)
Jul 21, 2025

Reported lobbying issue

Copyright/Patent/Trademark: I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act from last Congress, H.R.4370, S.2220), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act from last Congress (S.2140, H.R.9474). I have also supported disclosure of third-party litigation funding in patent cases (e.g., H.R.1109 - Litigation Transparency Act of 2025).

Government entities reported: Commerce, Dept of (DOC) Federal Trade Commission (FTC) HOUSE OF REPRESENTATIVES Justice, Dept of (DOJ) Patent & Trademark Office (PTO) SENATE White House Office

Reported filing-period amount: $110,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

HIGH TECH INVENTORS ALLIANCE

Registrant: DAVID W JONES

1st Quarter (Jan 1 - Mar 31)
Apr 21, 2025

Reported lobbying issue

Copyright/Patent/Trademark: I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act from last Congress, H.R.4370, S.2220), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act from last Congress (S.2140, H.R.9474).

Government entities reported: Commerce, Dept of (DOC) Federal Trade Commission (FTC) HOUSE OF REPRESENTATIVES Justice, Dept of (DOJ) Patent & Trademark Office (PTO) SENATE White House Office

Reported filing-period amount: $110,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗
Discussion notificationsSign in to subscribe
?
No comments yet. Start the conversation.